Home » Topics » Regulatory » EMA

EMA
RSS

European orphan drug status for Celldex Therapeutics' rindopepimut

Nov. 2, 2011

Amsterdam Molecular Therapeutics announces restructuring

Oct. 31, 2011

Lilly withdraws Xigris worldwide following PROWESS-SHOCK study

Oct. 26, 2011

EMA begins new review of Protelos and Osseor

Oct. 26, 2011

CHMP issues opinion on approval of Bronchitol

Oct. 25, 2011

CHMP maintains earlier opinion after reexamining Glybera MAA

Oct. 25, 2011

CHMP clarifies opinion on pioglitazone and the risk of bladder cancer

Oct. 24, 2011

EMA finds no link between cancer and use of angiotensin AT receptor antagonists

Oct. 21, 2011

Thrombogenics' ocriplasmin MAA accepted for review

Oct. 21, 2011

Isotechnika receives scientific advice from EMA for voclosporin trial

Oct. 19, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...